About 2 results

SGLT2, Fournier Gangrene Link Is 'Compelling'--What to Do?

Welcome to Impact Factor, your weekly commentary on a breaking medical study. I'm Perry Wilson. A new class of medications, the SGLT2 inhibitors, has been killing it lately, with study after study in the New England Journal of Medicine documenting their benefits in patients with diabetes. Many of us feel that these drugs will become a central part of diabetes therapy in the near future. The twi...

Are You Honest When Patients Ask, 'What Would You Do?'

This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine from the University of Oxford in England. I'd like to share with you a uniquely interesting consultation I had at clinic last week. It shouldn't be a surprise that, working in a large hospital in a university town like Oxford, we get a lot of academics as patients. They fall into two broad groups, a...